Navigation Links
Pain Killers To Carry Warnings About Heart Attack And Stroke Risk

Pain killers which are commonly used for a number of painful complaints, have been shown to increase the risk of heart attack and stroke//. This has lead to an order by the Commission on Human Medicines whereby these drugs will have to carry a warning along with the information put on them by the manufacturers.

Doctors are being informed of the small but increased risk in long term treatment with high doses of these drugs. These are used very commonly for conditions of chronic pain in osteoarthritis and rheumatoid arthritis, and are known as Non Steroidal Anti Inflammatory Drugs (NSAID).

Studies have shown that high doses(around 2400 mg) of these drugs increase the risk of heart attack, and an investigation into NSAIDs was launched last month by the European Medicines Agency.

Diclofenac, etodolac, ibuprofen, indomethacin, ketoprofen, ketorolac, meloxicam, nabumetone, naproxen, and nimesulide are the NSAIDS which have been reviewed. Low dose (400mg) ibuprofen which is an OTC drug is considered safe and will not have to include the cautionary information.

The director for vigilance and risk management, Medicines and Healthcare products Regulatory Agency, Dr. June Raine, said that the benefits of the drugs are still considered to outweigh the risks, and that it was not required that patients stop their medications if they felt well. However it is advisable to keep the treatment as low dose and short term as possible.
MAL
'"/>




Page: 1

Related medicine news :

1. Pain Killers Keep the Virus Away
2. Heart Related Problems-The Largest Killers In Andhra Pradesh
3. Cereal Killers: Is the Loaded Breakfast Bowl Really Healthy?
4. Copper Alloys Surfaces Touted As Pathogen Killers
5. Preventive Mastectomy Does Not Carry Emotional Baggage For Most Women
6. Well-Planned Surgeries Also Carry Health Risks
7. Cigarette Packets to Carry Skull-and-bones Sign
8. Apollo Group Permitted to Carry out Surgeries in its Oman Centre
9. Babies at Hospital found to Carry Super bug MRSA
10. Allergic Individuals Should Carry Two Doses Of EpiPen Says Quebec Coroner
11. Skin Lightening Products Carry Risk of Cancer
Post Your Comments:
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
(Date:12/4/2009)Increasing exercise, water and fruit consumption leads to success, study finds , , FRIDAY, Dec. 4 (HealthDay News) -- Increased exercise, reduced soda consumption and self-weighing are among
Breaking Medicine News(10 mins):Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Are angry women more like men? 2Health News:Teens Lose More Weight Using Healthy Strategies 2
...omen who got injections report reduced pain and s...) -- The first evidence that gene therapy can ease... has been reported by American and German research...e women,s affected joints. IL-1Ra protein blocks t...
... COLUMBUS, Ga., Feb. 6 Aflac Incorporated,annou... its holdings of,perpetual debenture securities at...nal information to its web site on each,Upper Tier... and elevated a frequently asked questions (FAQ) d...
...plies tend to run dangerously short this time of y... The holiday season is long gone, and everyone has... still one gift left to give, one that,s desperate...tions. Now that the new year is under way, there,s...
... This Valentine,s Day unpro... sweeteners and berries to produce a new type of c...rties. Dieting and the benefits of berry antioxida...ng been regarded as a sweet and sinful indulgence....
...utations could increase cancer risk almost 6-fold,...thDay News) -- Scientists have identified two gene...creased risk of developing thyroid cancer. , This ...cording to the U.S. National Cancer Institute. , "...
... KePRO,s Chief Medical Offi... care and quality of life , ...ce Stollenwerk Petrulis , MD, FACP, has been appoi...and care management, will work with other leading ...
Other Medicine News:Health News:Gene Therapy May Ease Rheumatoid Arthritis 2Health News:Aflac Incorporated Provides Added Detail on Perpetual Debenture Holdings 2Health News:Needed: Blood Donations 2Health News:Needed: Blood Donations 3Health News:Losing Weight with Chocolate on Valentine's Day 2Health News:Gene Test Could Predict Thyroid Cancer Risk 2Health News:Gene Test Could Predict Thyroid Cancer Risk 3Health News:Alice Stollenwerk Petrulis, MD, FACP, Appointed to NQF Care Coordination Committee 2
(Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is prese
(Date:12/4/2009)HOUSTON, Dec. 4 OrthoAccel Technologies, Inc., developers of the AcceleDent System , which is an acceleration device to enhance orthodontics, announced the availability of a new Continuing Education
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Stay Upbeat Active to Keep the Mind Young 49889 1Stay Upbeat Active to Keep the Mind Young 49889 2Stay Upbeat Active to Keep the Mind Young 49889 3WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 1WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 2WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 3WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 410th CyberKnife System Installed at an HCA Hospital 49885 110th CyberKnife System Installed at an HCA Hospital 49885 210th CyberKnife System Installed at an HCA Hospital 49885 310th CyberKnife System Installed at an HCA Hospital 49885 4
...rst study evaluating DUROS(R) continuous delivery ..., , HAYWARD, Calif., April 24 Intarcia Therapeut...t accrual to a phase 1b clinical study evaluating ...e). The study is being conducted at multiple cente... of 44 patients with type 2 diabetes for a period ...
...votal Trial Expected to Initiate in 2010 for Blina...asdaq: MITI ), a biopharmaceutical company devel...ent of cancer, inflammation and autoimmune disease...ancial analysts at The Yale Club of New York City....areas of development across Micromet,s BiTE antibo...
Other Medicine Technology:Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4
Serdarevic Suture Hook
Osher "Y" Hook
Fenzl Insertion Hook
Heath Chalazion Curette
Medicine Products: